Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEHRDAD KEVIN ARIANI

Allopathic & Osteopathic Physicians Internal Medicine Interventional Cardiology

NPI
1942496211
CMS profile
87900
Location
NORTHRIDGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$29,974.05

225 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEHRDAD KEVIN ARIANI

NPI 1942496211 · CMS profile ID 87900

Allopathic & Osteopathic Physicians / Internal Medicine / Interventional Cardiology

NORTHRIDGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1942496211?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEHRDAD KEVIN ARIANI, NPI 1942496211, CMS profile ID 87900. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1942496211?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MEHRDAD KEVIN ARIANI, NPI 1942496211, CMS profile ID 87900. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1942496211?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MEHRDAD KEVIN ARIANI, NPI 1942496211, CMS profile ID 87900, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 225 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1942496211?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

225 matching records · $29,974.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 225 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 225.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $125.0005/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810686161 CMS
PFIZER INC. $21.5005/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832512447 CMS
Alnylam Pharmaceuticals Inc. $28.4705/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 828515125 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $6.8405/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768787406 CMS
ABIOMED $117.4505/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848794527 CMS
AstraZeneca Pharmaceuticals LP $21.3505/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829946841 CMS
ABIOMED $23.6905/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848794513 CMS
SANOFI-AVENTIS U.S. LLC $22.6905/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843492905 CMS
Janssen Pharmaceuticals, Inc $5.0605/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788848337 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.0505/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763352892 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $3.6705/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768787404 CMS
Amgen Inc. $21.0305/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825607123 CMS
BOSTON SCIENTIFIC CORPORATION $126.1104/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777557429 CMS
Philips Electronics North America Corporation $151.9104/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853246059 CMS
Janssen Pharmaceuticals, Inc $21.8604/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788848341 CMS
Novartis Pharmaceuticals Corporation $22.6404/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812591157 CMS
E.R. Squibb & Sons, L.L.C. $13.8904/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783564743 CMS
ABIOMED $32.6404/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848794485 CMS
Abbott Laboratories $87.6004/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815475281 CMS
Novo Nordisk Inc $15.1604/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811357331 CMS
Amgen Inc. $23.1204/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825607115 CMS
Amgen Inc. $1.6704/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825607119 CMS
Janssen Pharmaceuticals, Inc $19.5904/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788848343 CMS
AstraZeneca Pharmaceuticals LP $20.7004/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829364387 CMS
Merck Sharp & Dohme Corporation $24.5604/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848413951 CMS
Takeda Pharmaceuticals U.S.A., Inc. $28.0604/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819853129 CMS
Medtronic, Inc. $13.7604/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815691559 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $6.1704/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768787402 CMS
Amarin Pharma Inc. $18.9003/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815113945 CMS
Astellas Pharma US Inc $13.6603/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821249623 CMS
Janssen Pharmaceuticals, Inc $23.7103/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788848333 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.4203/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819853127 CMS
Amgen Inc. $20.6503/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825607111 CMS
Janssen Pharmaceuticals, Inc $21.6703/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788848311 CMS
Novartis Pharmaceuticals Corporation $18.2203/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812591155 CMS
AstraZeneca Pharmaceuticals LP $24.0303/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829911645 CMS
Janssen Pharmaceuticals, Inc $4.0803/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788848313 CMS
ABIOMED $28.7103/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848794491 CMS
AstraZeneca Pharmaceuticals LP $100.0003/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829725665 CMS
Novartis Pharmaceuticals Corporation $23.0103/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812591153 CMS
Novo Nordisk Inc $32.2703/12/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 810828709 CMS
ABIOMED $29.7103/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848794487 CMS
Janssen Pharmaceuticals, Inc $19.5703/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788848305 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $5.9603/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768787400 CMS
CathWorks, Inc. $14.1403/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853620505 CMS
Merck Sharp & Dohme Corporation $24.5303/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848415251 CMS
ARBOR PHARMACEUTICALS, INC. $18.5302/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830923131 CMS
AstraZeneca Pharmaceuticals LP $950.0002/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829379921 CMS
AstraZeneca Pharmaceuticals LP $950.0002/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829398759 CMS
Amgen Inc. $21.0302/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825607103 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $8,679.45 148
PY2020 $7,223.81 144
PY2021 $29,974.05 225
PY2022 $31,275.53 223
PY2023 $8,580.32 176
PY2024 $3,865.35 128
PY2025 $5,011.01 140

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,801,699.26 89
PY2024 Recipient $61,134.47 7
PY2024 Principal investigator $784,679.33 34
PY2023 Recipient $50.00 1
PY2023 Principal investigator $658,346.59 98
PY2022 Recipient $50.00 1
PY2022 Principal investigator $539,235.86 83
PY2021 Recipient $9,400.00 1
PY2021 Principal investigator $265,601.96 187
PY2020 Principal investigator $397,144.96 150
PY2019 Principal investigator $452,933.67 150

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

89 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $9,108.34 12/31/2025 Non-covered Recipient Entity
Valley Clinical Trials Inc
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920033
Principal investigator 1 Ionis Pharmaceuticals, Inc. $90.00 12/30/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246792215
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 12/17/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715311
Principal investigator 1 Boehringer Ingelheim International GmbH $1,575.00 12/17/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715313
Principal investigator 1 Boehringer Ingelheim International GmbH $1,016.00 12/17/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715315
Principal investigator 1 Boehringer Ingelheim International GmbH $2,470.00 12/12/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715317
Principal investigator 1 Boehringer Ingelheim International GmbH $171.00 12/12/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715319
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,870.00 12/10/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246791447
Principal investigator 1 Boehringer Ingelheim International GmbH $3,828.00 11/19/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715297
Principal investigator 1 Boehringer Ingelheim International GmbH $3,828.00 11/19/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715299
Principal investigator 1 Boehringer Ingelheim International GmbH $3,475.00 11/19/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715301
Principal investigator 1 Boehringer Ingelheim International GmbH $3,623.00 11/19/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715303
Principal investigator 1 Boehringer Ingelheim International GmbH $2,470.00 11/19/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715305
Principal investigator 1 Boehringer Ingelheim International GmbH $171.00 11/19/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715307
Principal investigator 1 Boehringer Ingelheim International GmbH $3,623.00 11/19/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715309
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 11/19/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715321
Principal investigator 1 Impulse Dynamics (USA) Inc. $630.00 11/13/2025 Non-covered Recipient Entity
Valley Clinical Trials
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214123218
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 11/11/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996968
Principal investigator 1 Boehringer Ingelheim International GmbH $900.00 11/10/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715295
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 10/22/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996966
Principal investigator 1 Boehringer Ingelheim International GmbH $3,475.00 10/20/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715287
Principal investigator 1 Ionis Pharmaceuticals, Inc. $575.00 10/14/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789268
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,000.00 10/14/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789272
Principal investigator 1 Ionis Pharmaceuticals, Inc. $5,000.00 10/14/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789275
Principal investigator 1 Ionis Pharmaceuticals, Inc. $5,200.00 10/14/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789279
Principal investigator 1 Ionis Pharmaceuticals, Inc. $24,842.70 10/14/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789283
Principal investigator 1 Boehringer Ingelheim International GmbH $500.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715253
Principal investigator 1 Boehringer Ingelheim International GmbH $2,618.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715255
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715257
Principal investigator 1 Boehringer Ingelheim International GmbH $2,500.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715259
Principal investigator 1 Boehringer Ingelheim International GmbH $14,000.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715261
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715263
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715265
Principal investigator 1 Boehringer Ingelheim International GmbH $2,400.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715267
Principal investigator 1 Boehringer Ingelheim International GmbH $3,828.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715269
Principal investigator 1 Boehringer Ingelheim International GmbH $3,828.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715271
Principal investigator 1 Boehringer Ingelheim International GmbH $3,828.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715273
Principal investigator 1 Boehringer Ingelheim International GmbH $3,623.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715275
Principal investigator 1 Boehringer Ingelheim International GmbH $2,470.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715277
Principal investigator 1 Boehringer Ingelheim International GmbH $171.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715279
Principal investigator 1 Boehringer Ingelheim International GmbH $3,623.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715281
Principal investigator 1 Boehringer Ingelheim International GmbH $2,470.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715283
Principal investigator 1 Boehringer Ingelheim International GmbH $171.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715285
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715289
Principal investigator 1 Boehringer Ingelheim International GmbH $2,000.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715291
Principal investigator 1 Boehringer Ingelheim International GmbH $1,250.00 10/02/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715293
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 09/30/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996964
Principal investigator 1 Novartis Pharmaceuticals Corporation $41,443.48 09/30/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
Evaluation of Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (V-INTERVENTION) No dispute reported 06/30/2026 1190313599
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 09/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715251
Principal investigator 1 Amgen Inc. $81,885.60 09/23/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS, INC.
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246651130
Principal investigator 1 Novartis Pharmaceuticals Corporation $20,500.00 09/18/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190309570
Principal investigator 1 Impulse Dynamics (USA) Inc. $910.00 09/15/2025 Non-covered Recipient Entity
Valley Clinical Trials
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214123202
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,708.25 09/11/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] No dispute reported 06/30/2026 1190298573
Principal investigator 1 Ionis Pharmaceuticals, Inc. $450.00 09/09/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246787273
Principal investigator 1 Merck Sharp & Dohme LLC $23,450.20 09/08/2025 Non-covered Recipient Entity
Valley Clinical Trials Inc
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 1232920031
Principal investigator 1 Organon Llc $2,500.00 09/08/2025 Non-covered Recipient Entity
Valley Clinical Trials Inc
1242-035 No dispute reported 06/30/2026 1173042168
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 08/26/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715249
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,159.22 08/19/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190298570
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,628.38 08/19/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190298578
Principal investigator 1 Impulse Dynamics (USA) Inc. $700.00 08/14/2025 Non-covered Recipient Entity
Valley Clinical Trials
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214123200
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 08/12/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996962
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 07/30/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715245
Principal investigator 1 Amgen Inc. $3,487.19 07/28/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) No dispute reported 06/30/2026 1246651158
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 07/28/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715247
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 07/18/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996960
Principal investigator 1 Ionis Pharmaceuticals, Inc. $460.00 07/02/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246784996
Principal investigator 1 Ionis Pharmaceuticals, Inc. $600.00 07/02/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246785001
Principal investigator 1 Ionis Pharmaceuticals, Inc. $650.00 07/02/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS LLC DBA FLOURISH RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246785005
Principal investigator 1 Amgen Inc. $103,053.28 06/26/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS, INC.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246651134
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 06/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715239
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 06/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715241
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 06/24/2025 Non-covered Recipient Entity
Valley Clinical Trials
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220715243
Principal investigator 1 Amgen Inc. $13,825.66 06/20/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246651161
Principal investigator 1 Impulse Dynamics (USA) Inc. $35.00 06/12/2025 Non-covered Recipient Entity
Valley Clinical Trials
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214123204
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,338.00 06/11/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol No dispute reported 06/30/2026 1185551295
Principal investigator 1 Impulse Dynamics (USA) Inc. $735.00 05/14/2025 Non-covered Recipient Entity
Valley Clinical Trials
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214123216
Principal investigator 1 Novartis Pharmaceuticals Corporation $92,561.85 04/07/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
HPS-4/TIMI 65/ORION-4: A Double-blind Randomized Placebo-controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease No dispute reported 06/30/2026 1190313593
Principal investigator 1 Impulse Dynamics (USA) Inc. $630.00 03/26/2025 Non-covered Recipient Entity
Valley Clinical Trials
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214123214
Principal investigator 1 Impulse Dynamics (USA) Inc. $250.00 03/13/2025 Non-covered Recipient Entity
Valley Clinical Trials
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214123206
Principal investigator 1 Impulse Dynamics (USA) Inc. $250.00 03/13/2025 Non-covered Recipient Entity
Valley Clinical Trials
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214123208
Principal investigator 1 Impulse Dynamics (USA) Inc. $300.00 03/13/2025 Non-covered Recipient Entity
Valley Clinical Trials
Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) No dispute reported 06/30/2026 1214123210
Principal investigator 1 Impulse Dynamics (USA) Inc. $405.00 02/27/2025 Non-covered Recipient Entity
Valley Clinical Trials
Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) No dispute reported 06/30/2026 1214123212
Principal investigator 1 Eli Lilly and Company $7,540.56 02/25/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187892774
Principal investigator 1 AstraZeneca UK Limited $541,597.30 01/29/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Phase IIb Two cohort Randomised Placebo controlled Double blind Multicentre Dose ranging Study of AZD5462 in Stable Patients with Chronic Heart Failure No dispute reported 06/30/2026 1185551293
Principal investigator 1 Novartis Pharmaceuticals Corporation $77,790.26 01/27/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190313595
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,139.76 01/15/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190313607
Principal investigator 1 AstraZeneca UK Limited $181,295.00 01/13/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol No dispute reported 06/30/2026 1185551291
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,930.13 01/07/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS
A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein(a) lowering with pelacarsen (TQJ230) on the progression of calcific aortic valve stenosis [Lp(a)FRONTIERS CAVS] No dispute reported 06/30/2026 1190313601
Principal investigator 1 Eli Lilly and Company $390,422.00 01/06/2025 Non-covered Recipient Entity
VALLEY CLINICAL TRIALS INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187892602